Serviços Personalizados
Artigo
Indicadores
Links relacionados
- Citado por Google
- Similares em Google
Compartilhar
Southern African Journal of HIV Medicine
versão On-line ISSN 2078-6751
versão impressa ISSN 1608-9693
Resumo
SPIES, Ruan et al. Rifampicin resistance and mortality in patients hospitalised with HIV-associated tuberculosis. South. Afr. j. HIV med. (Online) [online]. 2022, vol.23, n.1, pp.1-8. ISSN 2078-6751. http://dx.doi.org/10.4102/sajhivmed.v23i1.1396.
BACKGROUND: Patients with HIV and drug-resistant tuberculosis (TB) are at high risk of death. OBJECTIVES: We investigated the association between rifampicin-resistant TB (RR-TB) and mortality in a cohort of patients who were admitted to hospital at the time of TB diagnosis. METHOD: Adults hospitalised at Khayelitsha Hospital and diagnosed with HIV-associated TB during admission, were enrolled between 2013 and 2016. Clinical, biochemical and microbiological data were prospectively collected and participants were followed up for 12 weeks RESULTS: Participants with microbiologically confirmed TB (n = 482) were enrolled a median of two days (interquartile range [IQR]: 1-3 days) following admission. Fifty-three participants (11.0%) had RR-TB. Participants with rifampicin-susceptible TB (RS-TB) received appropriate treatment a median of one day (IQR: 1-2 days) following enrolment compared to three days (IQR: 1-9 days) in participants with RR-TB. Eight participants with RS-TB (1.9%) and six participants with RR-TB (11.3%) died prior to the initiation of appropriate treatment. Mortality at 12 weeks was 87/429 (20.3%) in the RS-TB group and 21/53 (39.6%) in the RR-TB group. RR-TB was a significant predictor of 12-week mortality (hazard ratio: 1.88; 95% confidence interval: 1.07-3.29; P = 0.03. CONCLUSION: Mortality at 12 weeks in participants with RR-TB was high compared to participants with RS-TB. Delays in the initiation of appropriate treatment and poorer regimen efficacy are proposed as contributors to higher mortality in hospitalised patients with HIV and RR-TB.
Palavras-chave : HIV-associated tuberculosis; rifampicin-resistant tuberculosis; drug-resistant tuberculosis; multi-drug resistant TB; TB; Khayelitsha Hospital.